These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28426675)

  • 1. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.
    Patel H; Lissoos T; Rubin DT
    PLoS One; 2017; 12(4):e0175099. PubMed ID: 28426675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
    Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
    Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.
    Limketkai BN; Singh S; Jairath V; Sandborn WJ; Dulai PS
    Inflamm Bowel Dis; 2019 Oct; 25(11):1828-1837. PubMed ID: 31039246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.
    Rubin DT; Patel H; Shi S; Mody R
    Curr Med Res Opin; 2017 Mar; 33(3):529-536. PubMed ID: 27903084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center.
    Szántó K; Nyári T; Bálint A; Bor R; Milassin Á; Rutka M; Fábián A; Szepes Z; Nagy F; Molnár T; Farkas K
    PLoS One; 2018; 13(7):e0200824. PubMed ID: 30059523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis.
    Law CCY; Tkachuk B; Lieto S; Narula N; Walsh S; Colombel JF; Ungaro RC
    Inflamm Bowel Dis; 2024 Jul; 30(7):1080-1086. PubMed ID: 37506265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.
    Yamamoto-Furusho JK; Al Harbi O; Armuzzi A; Chan W; Ponce de Leon E; Qian J; Shapina M; Toruner M; Tu CH; Ye BD; Guennec M; Sison C; Demuth D; Fadeeva O; Khan QMR
    Dig Liver Dis; 2020 Aug; 52(8):869-877. PubMed ID: 32563721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.
    Gibble TH; Naegeli AN; Grabner M; Isenberg K; Shan M; Teng CC; Curtis JR
    BMC Gastroenterol; 2023 Mar; 23(1):63. PubMed ID: 36894911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study.
    Gagnon-Sanschagrin P; Sanon M; Davidson M; Willey C; Kachroo S; Hoops T; Naessens D; Guerin A; Cloutier M
    J Med Econ; 2024; 27(1):931-940. PubMed ID: 38965985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD.
    Click B; Barnes EL; Cohen BL; Sands BE; Hanson JS; Rubin DT; Dubinsky MC; Regueiro M; Gazis D; Crawford JM; Long MD
    BMC Gastroenterol; 2022 Feb; 22(1):71. PubMed ID: 35183108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study.
    Lirhus SS; Høivik ML; Moum B; Melberg HO
    Scand J Gastroenterol; 2018 Aug; 53(8):952-957. PubMed ID: 30205699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010.
    Shivashankar R; Tremaine WJ; Harmsen WS; Loftus EV
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):857-863. PubMed ID: 27856364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis.
    Odes S; Vardi H; Friger M; Esser D; Wolters F; Moum B; Waters H; Elkjaer M; Bernklev T; Tsianos E; O'Morain C; Stockbrügger R; Munkholm P; Langholz E
    Aliment Pharmacol Ther; 2010 Apr; 31(7):735-44. PubMed ID: 20047578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
    Colombel JF; Sandborn WJ; Reinisch W; Peyrin-Biroulet L; Panaccione R; Rutgeerts P; Hanauer SB; Ghosh S; Van Assche G; Robinson AM; Lau W; Maa JF; Huang B; Pappalardo B; Read H
    Aliment Pharmacol Ther; 2018 Jan; 47(2):219-228. PubMed ID: 29159817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients.
    Simian D; Fluxá D; Flores L; Lubascher J; Ibáñez P; Figueroa C; Kronberg U; Acuña R; Moreno M; Quera R
    World J Gastroenterol; 2016 Jun; 22(22):5267-75. PubMed ID: 27298570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
    Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
    Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.